TAT 2018 - Targeted Anticancer Therapies

Oncology Meeting Resources

05 Mar - 07 Mar 2018, Paris, France

TAT 2018

TAT 2018 - Targeted Anticancer Therapies focuses on early-phase development and translational research. The programme covered targeted agents, immuno-oncology and combinations involving such agents. Presentations and webcasts from the TAT 2018 - Targeted Anticancer Therapies are available here to ESMO members.

Watch ESMO video reports from experts:

The use of these presentations is for personal educational purposes only. ESMO thanks the authors for their generosity. Meeting programme  | Future ESMO meetings





Format available

https://oncologypro.esmo.org/Meeting-Resour...ncer-Therapies/Other-uses-of-PI3K-inhibitors

Most solid tumours demonstrate genetic activation of the PI3K pathway. However, the clinical impact of PI3K-inhibitors, aimed at dampening cancer-cell-intrinsic PI3K activity, has been limited.

Date: 07 Mar 2018
Presenter: Bart Vanhaesebroeck
Resources: Abstract, Presentation, Webcast

https://oncologypro.esmo.org/Meeting-Resour.../Impact-of-microbiome-on-the-efficacy-of-ICI

Date: 07 Mar 2018
Presenter: Giorgio Trinchieri
Resources: Presentation, Webcast

https://oncologypro.esmo.org/Meeting-Resour...apeutic-strategy-and-the-many-ongoing-trials

Date: 07 Mar 2018
Presenter: Aurelien Marabelle
Resources: Presentation, Webcast

https://oncologypro.esmo.org/Meeting-Resour...n-Immunotherapy-is-Disease-Context-Dependent

Date: 07 Mar 2018
Presenter: Lawrence Fong
Topic: Immunotherapy

https://oncologypro.esmo.org/Meeting-Resour...yper-progressive-disease-under-immunotherapy

Immunotherapy with immune checkpoint inhibitors (ICIs) is modifying the standard of care for several solid tumours. Nevertheless, the results in terms of efficacy are still limited to a minority of...

Date: 07 Mar 2018
Presenter: Filippo Guglielmo de Braud
Resources: Abstract, Presentation, Webcast
Topic: Immunotherapy

https://oncologypro.esmo.org/Meeting-Resour...AVID100-an-anti-EGFR-antibody-drug-conjugate

AVID100, an anti-EGFR-DM1 conjugate, showed potent activity in preclinical models in vitro and in vivo including in cell lines resistant to approved anti-EGFR mAbs.

Date: 07 Mar 2018
Presenter: Anthony Tolcher
Resources: Abstract, Presentation, Webcast
Topic: Anticancer Agents

https://oncologypro.esmo.org/Meeting-Resour...s/Next-generation-of-radio-immunotherapy-RIT

Targeted alpha therapy (TAT) involves selective delivery of isotopes that emit highly energetic alpha particles to cancer cells leading to their ultimate destruction, while minimizing collateral damage to healthy surrounding cells.

Date: 07 Mar 2018
Presenter: Istvan Molnar
Resources: Abstract, Presentation, Webcast
Topic: Immunotherapy

https://oncologypro.esmo.org/Meeting-Resour...ancer-Therapies/Take-home-messages-and-close

Date: 07 Mar 2018
Presenter: Giuseppe Giaccone